Chemoradiation is considered a reasonable treatment option for patients with locally advanced, unresectable pancreatic cancer. The chemotherapy agents 5-fluorouracil, gemcitabine, capecitabine and ...

Classification of Locally Advanced Pancreatic Adenocarcinoma Into Type A and B and Comparison With Definitions Used ... we would complete neoadjuvant therapy with chemoradiation delivered with ...

Novocure (NVCR) plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3. The company is also exploring the use of TTFields ...

evaluated TTFields therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The trial met its primary ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

NRG1 Gene Fusion Positive Unresectable or Metastatic NSCLC ... In the NRG1+ pancreatic adenocarcinoma group, the median age was 49 years (range, 21-72 years); 43% were female; 87% were White ...

including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other ...